Spero Therapeutics IncNASDAQ:SPRO
- LAST PRICE0.8000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.7800/ 20
- Ask / Lots0.8300/ 24
- Open / Previous Close0.0000 / 0.8000
- Day Range---
- 52 Week Range
- Volume1,511
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SPRO |
|---|---|---|
| 09:32 ET | 2430 | 0.8 |
| 09:34 ET | 1000 | 0.7999 |
| 09:39 ET | 400 | 0.7887 |
| 09:43 ET | 12840 | 0.7973 |
| 09:45 ET | 250 | 0.78 |
| 09:48 ET | 5400 | 0.7911 |
| 09:50 ET | 100 | 0.7955 |
| 09:57 ET | 4068 | 0.7887 |
| 10:01 ET | 100 | 0.7885 |
| 10:08 ET | 1200 | 0.7974 |
| 10:12 ET | 300 | 0.7974 |
| 10:14 ET | 1314 | 0.7974 |
| 10:17 ET | 689 | 0.7999 |
| 10:26 ET | 100 | 0.7999 |
| 10:35 ET | 100 | 0.7999 |
| 10:46 ET | 600 | 0.7999 |
| 10:50 ET | 125 | 0.789 |
| 10:51 ET | 100 | 0.79445 |
| 10:57 ET | 100 | 0.7999 |
| 11:00 ET | 200 | 0.7944 |
| 11:02 ET | 100 | 0.79495 |
| 11:08 ET | 400 | 0.79495 |
| 11:11 ET | 400 | 0.798 |
| 11:13 ET | 100 | 0.79495 |
| 11:27 ET | 200 | 0.79495 |
| 11:31 ET | 38753 | 0.79495 |
| 11:44 ET | 2100 | 0.79495 |
| 11:45 ET | 200 | 0.79495 |
| 11:47 ET | 1900 | 0.7983 |
| 11:51 ET | 700 | 0.7922 |
| 11:56 ET | 1700 | 0.81 |
| 11:58 ET | 1488 | 0.813 |
| 12:00 ET | 200 | 0.8063 |
| 12:02 ET | 1105 | 0.8126 |
| 12:03 ET | 14663 | 0.8298 |
| 12:05 ET | 200 | 0.8298 |
| 12:07 ET | 100 | 0.8299 |
| 12:09 ET | 9383 | 0.83 |
| 12:14 ET | 625 | 0.8002 |
| 12:16 ET | 100 | 0.8213 |
| 12:18 ET | 2900 | 0.82 |
| 12:21 ET | 200 | 0.8163 |
| 12:23 ET | 200 | 0.8126 |
| 12:25 ET | 6490 | 0.804 |
| 12:36 ET | 200 | 0.8095 |
| 12:38 ET | 900 | 0.79945 |
| 12:41 ET | 150 | 0.8 |
| 12:48 ET | 527 | 0.795 |
| 12:50 ET | 1095 | 0.7822 |
| 12:52 ET | 100 | 0.7819 |
| 12:54 ET | 100 | 0.7776 |
| 12:59 ET | 13052 | 0.784 |
| 01:01 ET | 100 | 0.7838 |
| 01:03 ET | 850 | 0.7844 |
| 01:14 ET | 100 | 0.7889 |
| 01:15 ET | 1100 | 0.7843 |
| 01:26 ET | 100 | 0.7926 |
| 01:37 ET | 300 | 0.78445 |
| 01:39 ET | 750 | 0.785 |
| 01:42 ET | 100 | 0.780325 |
| 01:44 ET | 100 | 0.7889 |
| 01:46 ET | 800 | 0.7889 |
| 01:48 ET | 203 | 0.7852 |
| 01:53 ET | 100 | 0.7853 |
| 02:00 ET | 100 | 0.8134 |
| 02:02 ET | 100 | 0.8017 |
| 02:08 ET | 100 | 0.8017 |
| 02:11 ET | 400 | 0.80175 |
| 02:15 ET | 100 | 0.795925 |
| 02:20 ET | 425 | 0.8134 |
| 02:24 ET | 100 | 0.80175 |
| 02:26 ET | 100 | 0.80175 |
| 02:27 ET | 100 | 0.7901 |
| 02:29 ET | 300 | 0.7957 |
| 02:31 ET | 7816 | 0.8041 |
| 02:33 ET | 400 | 0.80205 |
| 02:36 ET | 100 | 0.7907 |
| 02:38 ET | 1400 | 0.802 |
| 02:40 ET | 100 | 0.7907 |
| 02:42 ET | 500 | 0.7907 |
| 02:44 ET | 100 | 0.7907 |
| 02:45 ET | 100 | 0.7907 |
| 02:47 ET | 417 | 0.7907 |
| 02:49 ET | 200 | 0.7907 |
| 02:54 ET | 200 | 0.8006 |
| 02:56 ET | 100 | 0.7907 |
| 02:58 ET | 800 | 0.7907 |
| 03:02 ET | 200 | 0.80035 |
| 03:03 ET | 200 | 0.7907 |
| 03:05 ET | 515 | 0.81 |
| 03:07 ET | 200 | 0.81 |
| 03:09 ET | 800 | 0.80035 |
| 03:12 ET | 100 | 0.7907 |
| 03:18 ET | 300 | 0.7907 |
| 03:20 ET | 2998 | 0.81 |
| 03:21 ET | 100 | 0.8004 |
| 03:23 ET | 200 | 0.8005 |
| 03:25 ET | 500 | 0.8005 |
| 03:27 ET | 200 | 0.8005 |
| 03:30 ET | 100 | 0.791 |
| 03:32 ET | 300 | 0.81 |
| 03:34 ET | 100 | 0.7911 |
| 03:36 ET | 189 | 0.8005 |
| 03:38 ET | 400 | 0.81 |
| 03:39 ET | 4700 | 0.7914 |
| 03:43 ET | 200 | 0.8097 |
| 03:45 ET | 2630 | 0.80515 |
| 03:48 ET | 2600 | 0.8052 |
| 03:50 ET | 400 | 0.79 |
| 03:52 ET | 200 | 0.81 |
| 03:57 ET | 400 | 0.815 |
| 03:59 ET | 6027 | 0.8 |
Jul 25, 2022
DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 25, 2022 in Spero Lawsuit - SPRO, from 5:31PM ET on Monday Jul 25, 2022 by Newsfile
5:31PM ET on Monday Jul 25, 2022 by NewsfileSHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SPRO, from 3:56PM ET on Monday Jul 25, 2022 by PR Newswire
3:56PM ET on Monday Jul 25, 2022 by PR NewswireLAWSUITS-FILED-AGAINST-SPRO-WM-and-NOTV-Jakubowitz-Law-Pursues-Shareholders-Claims, from 2:15PM ET on Monday Jul 25, 2022 by Accesswire
2:15PM ET on Monday Jul 25, 2022 by AccesswireSpero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm, from 1:06PM ET on Monday Jul 25, 2022 by GlobeNewswire
1:06PM ET on Monday Jul 25, 2022 by GlobeNewswireThe Gross Law Firm Announces Class Actions on Behalf of Shareholders of SPRO, OM and MF, from 12:30PM ET on Monday Jul 25, 2022 by Accesswire
12:30PM ET on Monday Jul 25, 2022 by Accesswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Spero Therapeutics Inc | 26.3M | -0.2x | --- |
Aeglea Bio Therapeutics Inc | 25.7M | -0.4x | --- |
Obseva SA | 23.2M | -0.4x | --- |
Emmaus Life Sciences Inc | 18.3M | -2.0x | --- |
Viaderma Inc | 9.4M | 0.0x | --- |
Todos Medical Ltd | 25.5M | -0.6x | --- |
Company Information
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Its lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide), is developed as the oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). It is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. The Company also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.
Contact Information
- Headquarters
- 675 Massachusetts Ave Ste 14CAMBRIDGE, MA, United States 02139-3309
- Phone
- 857-242-1600
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Milind Deshpande
- President, Chief Executive Officer, Director
- Ankit Mahadevia
- Chief Financial Officer
- Satyavrat Shukla
- Chief Legal Officer
- Tamara Joseph
- Chief Development Officer
- Timothy Keutzer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $26.3M |
|---|---|
Revenue (TTM) | $13.0M |
Shares Outstanding | 32.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.94 |
EPS | $-3.24 |
Book Value | $2.73 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 2.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -758.35% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
